Alzamend Neuro Inc (ALZN) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.89 (+2.72%), Market cap $0.00B, 52-week low–high $0.54 ~ $5.44.
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is
Financial statements, price targets, institutional (13F) holdings and related news for Alzamend Neuro Inc are updated in real time on BlackAll Trade.
Alzamend Neuro Inc trades at $1.89 (+2.72%). Real-time quotes and charts are available on BlackAll Trade.
Alzamend Neuro Inc has a market cap of about $0.00B.
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001,